Purpose&Contents : To licensing out of a novel hemophilia B drug, ISU304 to a multi-national pharmaceutical company after evaluation of superior efficacy and safety through nonclinical and clinical studies
Results
- Development of a CHO cell line ...
Purpose&Contents : To licensing out of a novel hemophilia B drug, ISU304 to a multi-national pharmaceutical company after evaluation of superior efficacy and safety through nonclinical and clinical studies
Results
- Development of a CHO cell line expressing a recombinant protein drug, ISU304
- Evaluation of safety and culture stability of the cell line
- Preparation of Master cell bank (MCB) and Working cell bank (WCB)
- Development of culture processes development to ensure high productivity
- Development of purification processes to obtain high purity and to remove
impurities
- Analysis of activity and characterization of ISU304, a recombinant protein drug
- Production of drug substance for nonclinical studies
- Development of processes making drug product (lyophilization)
- Validation of virus removal processes
- In vivo efficacy evaluation in comparison with current therapeutics in the market
- PK/PD of ISU304 in animal models (intravenous and subcutaneous administration)
- In vivo safety evaluation through GLP-Tox studies
- Production of drug product for clinical study
- Stability testing of drug product for clinical study
- Characterization of drug product for clinical study
Expected Contribution
- Development of a novel recombinant factor IX product enabling subcutaneous injection
- Phase 1 clinical trial confirming safety and feasibility of subcutaneous administration in hemophilia B patients
- Licensing out of ISU304 to a multi-national pharmaceutical company or clinical development of phase 2-3 by the partnering company, Catalyst Biosciences